Hengan International Founder Dies

MT NewswiresApr 22 00:36 ET

HENGAN INT'L (01044): Vice Chairman and Executive Director Xu Lianjie has passed away.

HENGAN INT'L (01044) announced that one of the founders of the group, the company's vice chairman and executive Director Xu Lianjie, will...

Zhitong FinanceApr 21 06:23 ET

HENGAN INT'L: ANNUAL REPORT 2024

HKEXApr 14 10:50 ET · Announcements

Hengan International Group Company Limited's (HKG:1044) Largest Shareholder, Senior Key Executive Lin Chit Hui Sees Holdings Value Fall by 3.0% Following Recent Drop

Simply Wall StApr 13 20:32 ET

UBS Group: Downgraded HENGAN INT'L Target Price to HKD 27, slightly weaker performance in the second half of last year.

UBS Group released a Research Report stating that HENGAN INT'L (01044) experienced a year-on-year decline in revenue and Net income of 4.6% and 17.9% last year, with revenue and Net income decreasing by 6.3% and 43.5% in the second half of last year, slightly below the bank's previous expectations. The bank has lowered its earnings forecasts for 2025 to 2027 by 7% to 8%, primarily to reflect the challenging Operation environment faced by HENGAN. The Target Price has been reduced from HKD 28.1 to HKD 27. HENGAN is currently trading at a 2025 PE of 10.5 times, with a dividend yield of 6.9%, indicating that the valuation is not high. The 'Buy' rating is maintained.

Sina Hong Kong StockMar 27 05:34 ET

BOCOM INTL: Maintain a "neutral" rating for HENGAN INT'L. Industry competition and raw material pressure continue.

BOCOM INTL released a Research Report stating that the competitive landscape in the Industry and rising raw material costs have placed slight pressure on HENGAN INT'L (01044) performance. The bank has lowered the company's Financial Estimates, setting a Target Price of HKD 22.64, based on a projected PE of 10.2 times for 2025. The rating is maintained at "Neutral." The bank indicates that in 2024, HENGAN Group's revenue is expected to decrease by 4.6% year-on-year, mainly due to intensified competition in the Industry and the impact of low-price promotions across various brands. Due to rising raw material costs in the tissue business, the gross margin has decreased by 1.4 percentage points. The Operating profit and Net income have declined by 5.7% and 17.9% respectively. The company maintains a stable dividend, distributing dividends per share for the entire year.

Sina Hong Kong StocksMar 27 05:09 ET